drugset / Trial / NCT01754818

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

NCT01754818

Phase 1 Completed 30 enrolled Stealth BioTherapeutics Inc.
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to assess the study medication blood levels after administration of a single oral capsule of Bendavia at one of three dose levels. The effects of Bendavia on the volunteers will also be assessed.

Timeline

Start
2012-11
Primary completion
2013-01
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 10 mg Oral
Subject Elamipretide Peptide 50 mg Oral
Subject Elamipretide Peptide 100 mg Oral

Indications

No indication recorded.